Oneview Healthcare (ASX:ONE) Shares Rally Despite Losses And Short Cash Runway

Oneview Healthcare just closed at A$0.195, capping a 30% gain over the past month. However, today’s H1 2026 numbers pulled investor attention back to a harder truth. This is still a growth story built on losses and a short cash runway, not a clean profitability pivot.

The market appears to be cheering progress in the recurring revenue mix and the move to a 70% gross margin. At the same time, Oneview Healthcare reported a net loss of €5.493m for the half and highlighted cash that covers less than a year, which keeps financing risk firmly in play.

Love the improving margins at Oneview Healthcare but concerned about the ongoing losses and short cash runway? Take a look at our hand picked list of list of solid balance sheet and fundamentals stocks (21 results)

H1 2026 Earnings Summary

• Revenue, H1 2026 vs H1 2025: €5.485m vs €6.342m (down 13.5%)
• Net Loss, H1 2026 vs H1 2025: €5.493m loss vs €7.888m loss (loss narrowed 30.3%)
• Basic EPS, H1 2026 vs H1 2025: €0.01 loss per share vs €0.01 loss per share (stable)
• Gross Margin, H1 2026 vs prior year: 70% vs 61% (up 9 percentage points)

Prefer clear visuals instead of scrolling through earnings tables and cash flow lines? Get a full picture of Oneview Healthcare with an easy to scan view of its balance sheet strength and funding needs in our company report for Oneview Healthcare.

Oneview’s SaaS shift hits key revenue milestones

Bulls argue that Oneview Healthcare can pivot from project work to a scalable, high margin SaaS engine. The latest half year gives that claim some real backing. Recurring revenue rose 13% on a reported basis and 20% in constant currency and now accounts for 79% of group revenue compared with 60% a year earlier. Gross margin lifted to 70%, which fits the story of a richer software mix and less reliance on lower margin hardware deployments. Cash OpEx fell 6% after the 2025 restructuring and the EBITDA loss narrowed 11%, which points to some operating leverage as recurring revenue builds. However, live endpoints only reached about 15,000 with additions held back by delays and decommissions. That means the revenue base is improving in quality, but the scale up of installed beds that bulls want to see is still incomplete.

Losses, cash runway and execution risks still bite

Bears focus on persistent losses, funding risk and slow conversion of a concentrated pipeline. H1 2026 does not remove those worries. Oneview Healthcare still reported a €5.493m net loss and operating cash outflow only improved 15%. Cash of €7.2m at 30 June, or €11.4m including the discretionary placement tranche, implies less than a year of cover at recent burn unless cash generation improves. That keeps the risk of further funding firmly on the table. Revenue concentration and timing risk are also visible. Total revenue declined 13.5% as deployments and hardware sales softened and a key Children’s Hospital of Ireland rollout slipped again, while 481 Australian endpoints were decommissioned in a pressured market. The pipeline around Bedside Hub and Baxter looks large, but as of today it is still largely unconverted, so the bearish view on execution and funding remains only partly challenged.

Compare Oneview Healthcare’s margin gains and recurring revenue push with how analysts are reacting to the losses and funding risk. See the consensus price target analysis for Oneview Healthcare to check where the street thinks ASX:ONE should be trading after these H1 2026 results.

Stay Ahead of Your Next Move

If Oneview Healthcare’s margin progress and funding risk mix has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for a setup that fits your plan. Once you own it or any other stock, use the Portfolio Command Center to keep focused on the key updates that matter instead of daily noise. For longer term context, tap into the Community to see how other investors are reacting as the story unfolds. Spot potential catalysts and risks earlier so you can act with more confidence and stay a step ahead of the market.

Seeking Alternatives Beyond Oneview Healthcare

Fresh ideas move first when momentum builds and quiet stories can fly before most investors notice. Scan these under the radar opportunities while the data still matters and get in early.

• Chase potential breakouts in smaller companies that already produce cash and carry cleaner balance sheets through our curated 11 high quality undiscovered gems
• Target steady income from businesses aiming to maintain high payouts and solid financial footing by reviewing the hand picked 8 dividend fortresses
• Ride the long term shift toward cleaner baseload power by weighing infrastructure stocks screened for fundamentals and momentum in the focused 92 nuclear energy infrastructure stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com